Prime Medicine develops one-time genetic medicines based on Prime Editing, a next-generation gene-editing approach designed to correct disease-causing DNA mutations with high precision and without relying on double-strand breaks. Its platform aims to repair a large share of known pathogenic mutations across many cell types and organs. Programs include ex vivo edited stem-cell therapies such as PM359 for chronic granulomatous disease, with potential expansion into other genetic and broader disease areas.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1.1 | — | -52.6 | — |
| Q3 2025 | 1.2 | — | -50.6 | — |
| Q4 2025 | 0.8 | — | -46.1 | — |
| Q1 2026 | 0.9 | — | -49.1 | — |
| Q2 2026 | 1.1 | 3.5% | -42.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: AgomAb Therapeutics NV (AGMB), Matthews International Corporation (MATW), Grid Dynamics Holdings, Inc. (GDYN), Drugs Made In America Acquisition II Corp. (DMII), OIO Group (OIO), CorMedix Inc. (CRMD)